Katheryne Richardson, PharmD (tentative)Executive Director and Head US 340B Strategy at Bristol Myers Squibb
Dr. Richardson is the Executive Director and Head of US 340B Strategy for Bristol-Myers Squibb. In this role, Dr. Richardson is responsible for leading and aligning 340B strategy across the BMS matrix, including with Sales, Marketing, Value and Access, Government Price Reporting, Policy/Government Affairs, and legal for the entire BMS portfolio. Additionally, she represents BMS in the external 340B environment and serves as the primary BMS voice to the 340B community.
Prior to joining Bristol-Myers Squibb, Dr. Richardson was the Vice President of Apexus, the 340B Prime Vendor Program, where she was responsible for the executive oversight of teams responsible for policy, education, and compliance. Under her leadership, the Apexus Answers Call Center, the 340B University, 340B OnDemand, and the Apexus Advanced 340B Operations Certificate Program were created and evolved to set industry standards. As a thought-leader, Dr. Richardson represented Apexus frequently at national presentations and was responsible for leading executive-level relationships with partner organizations. Additionally, she served on the Apexus senior leadership team responsible for the strategic direction, financial oversight, and overall business operations of the company.
Prior to Apexus, Dr. Richardson held a variety of roles of increasing responsibility in clinical practice, consulting, and public health, including experience at the Food and Drug Administration, National Institutes of Health and the Centers for Disease Control and Prevention.
Dr. Richardson is a graduate of the University of Kentucky College of Pharmacy, where she received her B.S. and PharmD degree. She received a certificate in Outcomes Research from the American Society of Health System Pharmacists and is a licensed pharmacist in Virginia.
Updated Data on Growth in 340B Programs and IRA Operationalization, 4:10pmView Session